In Search of Lost Biomarker for Immunotherapy in Small Cell Lung Cancer

Chemo-immunotherapy is the current standard of care for extensive-stage small cell lung cancer, but predictive biomarkers are lacking. In a recent article, the authors report the predictive role of programmed death ligand-1 expression and tissue tumor mutational burden on durvalumab tremelimumab + platinum-etoposide efficacy. See related article by Paz-Ares et al., p. 824